GENB GENB
Company Profile ↓Company Overview
GENB (GENB) is a publicly traded company listed on with a market capitalization of $1.85B. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Generates a return on equity of 33.0%, reflecting efficient use of shareholder capital.
Revenue has grown at a 55.9% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.13.
Recent Developments
- Dec 2025 Revenue of $31.89M (+55.9% YoY); net profit $-203.15M.
- Trailing 12 Months Year-on-year growth — revenue +55.9%.
- 5-Year Trend Long-term compounding — revenue CAGR 55.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 55.89% |
| 1 Year: | 55.89% |
Stock Price Performance
| 1 Year: | +14.55% |
| 6 Months: | - |
| 3 Months: | -6.03% |
| 1 Month: | -10.67% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- RSI (14)52.51 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 33.0%.
- Compounding revenue at 55.9% over 5 years.
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue | 8.82M | 7.22M |
| Cost of Revenue | - | - |
| Gross Profit | - | - |
| Operating Expenses | 56.97M | 71.34M |
| Operating Income | -48.15M | -64.11M |
| EBITDA | -40.48M | -58.23M |
| Interest Expense | 368.00K | 182.00K |
| Pretax Income | -44.26M | -61.69M |
| Tax Provision | 56.00K | 28.00K |
| Net Income | -41.69M | -61.45M |
| Diluted EPS | -0.52 | -1.07 |
| R&D Expense | 46.83M | 57.81M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Revenue | 20.46M | 31.89M |
| Cost of Revenue | - | - |
| Gross Profit | - | - |
| Operating Expenses | 217.40M | 266.96M |
| Operating Income | -196.94M | -235.06M |
| EBITDA | -163.71M | -208.49M |
| Interest Expense | 2.12M | 1.14M |
| Pretax Income | -181.17M | -222.80M |
| Tax Provision | 212.00K | 163.00K |
| Net Income | -173.77M | -203.15M |
| Diluted EPS | -2.09 | -2.18 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Total Assets | 518.26M | 330.18M |
| Current Assets | 407.49M | 234.37M |
| Cash & Equivalents | 176.27M | 121.65M |
| Inventory | - | - |
| Receivables | 308.00K | 0 |
| Total Liabilities | 953.35M | 953.38M |
| Current Liabilities | 86.63M | 82.20M |
| Long Term Debt | - | - |
| Total Debt | 76.97M | 68.53M |
| Total Equity | -434.52M | -615.97M |
| Shares Outstanding | 127.45M | 127.45M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Operating Cash Flow | -117.75M | -200.62M |
| Investing Cash Flow | -57.73M | 116.77M |
| Financing Cash Flow | 91.33M | 28.06M |
| Capital Expenditure | -3.45M | -3.51M |
| Free Cash Flow | -121.20M | -204.13M |
| Net Change in Cash | -84.15M | -55.79M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Gross Margin % | - | - |
| Operating Margin % | -962.6% | -737.0% |
| Net Margin % | -849.4% | -637.0% |
| ROE % | 40.0% | 33.0% |
| ROCE % | -45.6% | -94.8% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for GENB
Top Generate Biomedicines (GENB) Competitors 2026 - MarketBeat
<a href="https://news.google.com/rss/articles/CBMigAFBVV95cUxQMHpDLXBNa2VYbUZId1luWnVudFgzUXFXUFpwV2doLVYzVVJzWEEtcDRqOUtmSW9jM0NSQi1JM1FaQnRaSURrX3pkTjRfNXdSVVZUamkzS0U4VnlwQkt3c1pkOTRwRFdWWm9DQzBmUlRPcGFEd3hmcUF5QkNHcGFVeA?oc=5" target="_…
This Is Nvidia CEO Jensen Huang's Favorite Biotech Stock -- and You've Probably Never Heard of It - The Motley Fool
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxPalZHYUl5YklJM2VhWThuTVBuT29wYWRJZlVsemhlZEtiNHYyN0RoOW9jc002bExodFhUcVhWd1AyRllWN1Y2ZHI0by1fT0hQa1QxendodmZTZUVuckd6anRyZkF4SHhib1RkaDE5SzJMaExTbUIzWFkxOGtjdnUzY0JsUnpoVTJjMUhNTj…
A Look At Generate Biomedicines (GENB) Valuation As Shares Soften After Recent Gains - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxQbl9MSmQ4UjdTNEg4cTlEUUN3VUUwRzJHYk9uTTVZQXI4N2JWRWJQWlVoQXQ4VTc5Z3lKR1hvZjUxQUUxazFuOEJ5b1JrN1U3cHBpR2tuUGlWaTJaa1JWTW9TS0ttSU10LWJlVm1fcF9OeDdxd0p5dEIydDd6Y3J4U2NpTlJ2ZGt2N2hOSE…
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE51UmJlZ1EwS01oeUxCUkNFbHQyOHJEalZjLU9zbDJDWklRLV9ja2d0c3ZqZVpsdzZ2LXZDSDRTVVRISjhGdFFwb20wd0xwTUlW?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
If You Invested $1,000 in Generate Biomedicines (GENB) - Stock Titan
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE1oMlhGa1NiRmNnbUZXVjljcXBfR2Z6U041Z0t3aFdpc0NvNXVtRUdDdkw3ZWNsTHoyQUhlTGQ1LW96M0lremt3X2xDQmxtdjVfX3NNN2I0aXNBT1FGOUYtX1FUai0tMVpXX2dKLVhn?oc=5" target="_blank">If You Invested $1,…
Generate Biomedicines, Inc. (GENB) Return On Assets (TTM) - Zacks Investment Research
<a href="https://news.google.com/rss/articles/CBMie0FVX3lxTE43dFNwQXRNU21vNEFoc1Y0eU5vcmxSRUZMNEdhSGtPanpMN3hobE9uWUdGXzZZMWlTSjIxeGF6NkhtaWxsc0U4TmI4b3FiSV9sb1djX1ZhcnBrSDA2dkJLSF84RGtpdWVldUlVdmhQejBuQnZaeWlJVkl3cw?oc=5" target="_blank">G…
GENB — Frequently Asked Questions
What is the current share price of GENB?
As of 2026-08-05 17:25 PDT, GENB trades at $14.49 on NASDAQ/NYSE. Its 52-week range is $11.21 to $17.41.
What is the market capitalisation of GENB?
GENB has a market capitalisation of $1.85B on NASDAQ/NYSE.
What is the P/E ratio of GENB?
GENB trades at a trailing price-to-earnings (P/E) ratio of -6.65. Its price-to-book (P/B) ratio is -3.00.
What is the return on equity (ROE) of GENB?
GENB has a return on equity (ROE) of 32.98%. Its return on capital employed (ROCE) is -94.79%.
Is GENB a good stock to buy?
This page provides a data-driven analysis of GENB, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.